LNC
BLUE

Lincoln National Corp’s bluebird bio BLUE Stock Holding History

Lincoln National Corp’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-139
Closed -$321K – 503
2017
Q4 		$321K Buy
+139
New +$282K 0.01% 479

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Lincoln National Corp's BLUE Position: Q1 2018 in Review

Lincoln National Corp sold out of bluebird bio (BLUE) in Q1 2018, closing a stake of 139 shares — an estimated $321K sold.

Lincoln National Corp first reported a position in BLUE in Q4 2017 and held it in 1 quarter. The position peaked at $321K in Q4 2017. 303 funds tracked by Wall St. Rank hold BLUE as of Q1 2018.

  • Lincoln National Corp reported no remaining bluebird bio position as of Q1 2018 after selling out during the quarter.
  • Lincoln National Corp sold 139 bluebird bio shares in Q1 2018, an estimated $321K.
  • Lincoln National Corp first reported a position in bluebird bio in Q4 2017 and held it in 1 quarter.
  • Lincoln National Corp's bluebird bio position peaked at $321K in Q4 2017.
  • 303 funds tracked by Wall St. Rank held bluebird bio as of Q1 2018.

Based on Lincoln National Corp's 13F filing for Q1 2018, filed 9 May 2018.